Differansiye tiroid kanseri, d\u00fcnya genelinde en s\u0131k te\u015fhis edilen endokrin maligniteler aras\u0131nda yer almaktad\u0131r. Cerrahi rezeksiyonu takiben kullan\u0131lan radyoaktif iyot (RAI) tedavisi, \u00f6zellikle y\u00fcksek riskli hastalarda y\u0131llard\u0131r etkin bir tedavi y\u00f6ntemi olarak uygulanm\u0131\u015ft\u0131r. Ancak, d\u00fc\u015f\u00fck ve orta riskli diferansiye tiroid kanseri hastalar\u0131nda RAI tedavisinin uzun vadeli sa\u011fkal\u0131m \u00fczerine etkisi klinik anlamda tart\u0131\u015fmal\u0131 kalmaya devam etmi\u015ftir. Nisan 2025\u2019te The Journal of Nuclear Medicine dergisinde yay\u0131mlanan yeni bir ara\u015ft\u0131rma ise, farkl\u0131 risk kategorileri ve histolojik alt tiplerde RAI tedavisinin sa\u011fkal\u0131m avantaj\u0131n\u0131 b\u00fcy\u00fck \u00f6l\u00e7ekli retrospektif analizler \u0131\u015f\u0131\u011f\u0131nda g\u00fc\u00e7l\u00fc \u015fekilde destekleyen kan\u0131tlar sunmu\u015ftur.<\/p>\n
\u00c7al\u0131\u015fmada, Amerika Birle\u015fik Devletleri\u2019nin geni\u015f kapsaml\u0131 kanser kay\u0131tlar\u0131 aras\u0131nda yer alan Surveillance, Epidemiology, and End Results Program (SEER) veritaban\u0131ndan 101.000\u2019in \u00fczerinde hastaya ait ger\u00e7ek d\u00fcnya verileri de\u011ferlendirilmi\u015ftir. Ara\u015ft\u0131rmac\u0131lar, hastalar\u0131 histolojik s\u0131n\u0131fland\u0131rmaya g\u00f6re klasik papiller tiroid kanseri (PTC), agresif PTC varyantlar\u0131, folik\u00fcler tiroid kanseri (FTC) ve minimal invazif FTC olarak grupland\u0131rm\u0131\u015f; ayr\u0131ca hastalar klinik n\u00fcks riski d\u00fczeylerine g\u00f6re \u00e7ok d\u00fc\u015f\u00fck, d\u00fc\u015f\u00fck, orta ve y\u00fcksek risk olarak kategorize edilmi\u015ftir. Bu ayr\u0131m, tedavinin etkisini daha do\u011fru \u00f6l\u00e7mek i\u00e7in hastalar\u0131n sa\u011fkal\u0131mlar\u0131n\u0131n kanserli olmayan benzer bireylerle kar\u015f\u0131la\u015ft\u0131r\u0131ld\u0131\u011f\u0131 g\u00f6receli sa\u011fkal\u0131m analizini m\u00fcmk\u00fcn k\u0131lm\u0131\u015ft\u0131r.<\/p>\n
Sonu\u00e7lar, RAI tedavisinin \u00e7o\u011fu alt grupta belirgin sa\u011fkal\u0131m avantaj\u0131 sa\u011flad\u0131\u011f\u0131n\u0131 ortaya koymu\u015f ve bu durum, uzun s\u00fcredir s\u00fcregelen klinik tart\u0131\u015fmalar\u0131 yeniden g\u00fcndeme ta\u015f\u0131m\u0131\u015ft\u0131r. \u00d6zellikle y\u00fcksek riskli diferansiye tiroid kanseri grubunda 30.9% gibi dikkat \u00e7ekici bir sa\u011fkal\u0131m avantaj\u0131 saptanm\u0131\u015f; bu da RAI\u2019nin agresif hastal\u0131kta bilinen terap\u00f6tik de\u011ferini yeniden teyit etmektedir. Ayr\u0131ca, d\u00fc\u015f\u00fck ve orta risk gruplar\u0131nda da tedavinin k\u00fc\u00e7\u00fck ama tutarl\u0131 iyile\u015ftirici etkileri g\u00f6zlemlenmi\u015ftir. Klasik PTC hastalar\u0131nda, daha b\u00fcy\u00fck t\u00fcm\u00f6rler ve lenf nodu metastazlar\u0131n\u0131n varl\u0131\u011f\u0131nda RAI tedavisi, 10 y\u0131ll\u0131k g\u00f6receli sa\u011fkal\u0131m\u0131 %1.3 ile %2.0 aras\u0131nda art\u0131rm\u0131\u015ft\u0131r. Dikkat \u00e7ekici olarak, minimal invaziv FTC hastalar\u0131nda d\u00fc\u015f\u00fck risk grubunda da sa\u011fkal\u0131mda olumlu e\u011filimler kaydedilmi\u015ftir; bu durum RAI\u2019nin geleneksel endikasyonlar\u0131n d\u0131\u015f\u0131ndaki hastalarda da fayda sa\u011flayabilece\u011fine i\u015faret etmektedir.<\/p>\n
RAI tedavisinin mekanizmas\u0131, tiroid dokusunun iyot tutulumu \u00f6zelli\u011finden yararlanarak cerrahi sonras\u0131 kalan tiroid kanseri h\u00fccrelerine ya da mikrometastazlara hedeflenmi\u015f radyasyon sunmas\u0131d\u0131r. Bu hedefe y\u00f6nelik sitotoksisite, gizli hastal\u0131\u011f\u0131n yok edilmesinde ve n\u00fcks\u00fcn \u00f6nlenmesinde kritik \u00f6neme sahiptir. Y\u00fcksek riskli diferansiye tiroid kanserlerinde RAI kullan\u0131m\u0131 standart hale gelmi\u015f olmas\u0131na kar\u015f\u0131n, daha d\u00fc\u015f\u00fck risk grubundaki heterojen t\u00fcm\u00f6r biyolojisi ve hastal\u0131k seyri, klinik rehberliklerde uygulama farkl\u0131l\u0131klar\u0131na yol a\u00e7m\u0131\u015ft\u0131r. Bu \u00e7al\u0131\u015fma, histolojik alt tipler ve risk kategorileri \u00fczerinden kapsaml\u0131 bir analiz yaparak bu bo\u015fluklar\u0131 doldurmaya y\u00f6nelik \u00f6nemli bir veri seti sunmaktad\u0131r.<\/p>\n
Ara\u015ft\u0131rmada, RAI tedavisinin incelenen hi\u00e7bir alt grupta sa\u011fkal\u0131m a\u00e7\u0131s\u0131ndan olumsuz etkisi olmad\u0131\u011f\u0131 da rapor edilmi\u015ftir. Bu bulgu, klinisyenlerin adjuvan tedavi \u00f6nerirken risk-fayda analizlerini yaparken \u00f6nemli bir g\u00fcvence sa\u011flamaktad\u0131r. Ayr\u0131ca, sa\u011fkal\u0131mda iyile\u015fmenin tedaviden sonra yakla\u015f\u0131k sekiz y\u0131l i\u00e7inde belirgin hale gelmesi, tiroid kanseri sa\u011fkal\u0131m\u0131nda uzun d\u00f6nem izlem ve takip stratejilerinin gereklili\u011fini ortaya koymaktad\u0131r.<\/p>\n
Bu ara\u015ft\u0131rman\u0131n sonu\u00e7lar\u0131, klinik karar verme s\u00fcre\u00e7lerine ve tedavi rehberlerinin g\u00fcncellenmesine \u00f6nemli katk\u0131lar sunmaktad\u0131r. \u00d6nde gelen n\u00fckleer t\u0131p uzmanlar\u0131ndan Dr. Henning Weis, SEER gibi geni\u015f veri setlerinden elde edilen ger\u00e7ek d\u00fcnya kan\u0131tlar\u0131n\u0131n, randomize kontroll\u00fc \u00e7al\u0131\u015fmalar\u0131n s\u0131n\u0131rl\u0131 oldu\u011fu alanlarda klinik tart\u0131\u015fmalar\u0131 \u00e7\u00f6zmede kritik rol oynad\u0131\u011f\u0131n\u0131 belirtmi\u015ftir. Bu t\u00fcr \u00e7al\u0131\u015fmalar, diferansiye tiroid kanserinin yava\u015f ilerleyen do\u011fas\u0131 nedeniyle uzun d\u00f6nem sa\u011fkal\u0131m verilerinin toplanmas\u0131n\u0131n zorluklar\u0131n\u0131 a\u015fmak i\u00e7in b\u00fcy\u00fck \u00f6nem ta\u015f\u0131maktad\u0131r.<\/p>\n
Ara\u015ft\u0131rman\u0131n ortak yazar\u0131 Prof. Matthias Schmidt ise, tiroid kanseri tedavi rehberlerinin haz\u0131rlanmas\u0131nda ge\u00e7en yakla\u015f\u0131k on y\u0131ll\u0131k eme\u011fin sonunda bu analizlerin, RAI tedavisinin sa\u011fkal\u0131m \u00fczerindeki etkisini ampirik olarak destekleyen \u00f6nemli bir yap\u0131ta\u015f\u0131 oldu\u011funu vurgulam\u0131\u015ft\u0131r. Elde edilen veriler, n\u00fckleer t\u0131p ve endokrinoloji uzmanlar\u0131n\u0131n hastaya \u00f6zg\u00fc klinik detaylar\u0131 dikkate alarak tedavi planlar\u0131n\u0131 daha bilin\u00e7li ve g\u00fcvenle \u015fekillendirmesine zemin haz\u0131rlamaktad\u0131r.<\/p>\n
RAI tedavisinin sadece sa\u011fkal\u0131m\u0131 iyile\u015ftirmede de\u011fil, ayn\u0131 zamanda y\u00fcksek riskli diferansiye tiroid kanserlerinde n\u00fcks oranlar\u0131n\u0131 d\u00fc\u015f\u00fcrmeye y\u00f6nelik rol\u00fc de uzun s\u00fcredir kabul g\u00f6rmektedir. Bu b\u00fcy\u00fck \u00f6l\u00e7ekli \u00e7al\u0131\u015fma, sa\u011fkal\u0131m avantaj\u0131n\u0131 da do\u011frulayarak RAI\u2019nin hastal\u0131k kontrol\u00fc ile mortalite \u00fczerindeki \u00e7ift etkisini g\u00fc\u00e7lendirmi\u015ftir. Buna ek olarak, d\u00fc\u015f\u00fck ve orta riskli hastalarda adjuvan RAI kullan\u0131m\u0131na dair paradigmalar\u0131n de\u011fi\u015febilece\u011fini i\u015faret etmekte ve ki\u015fiselle\u015ftirilmi\u015f tedavi yakla\u015f\u0131mlar\u0131n\u0131n \u00f6nemini ortaya koymaktad\u0131r.<\/p>\n
\u00c7al\u0131\u015fman\u0131n retrospektif do\u011fas\u0131 ve kay\u0131t veritaban\u0131na dayanmas\u0131, g\u00f6zlemsel analizlere \u00f6zg\u00fc baz\u0131 k\u0131s\u0131tlamalar\u0131 beraberinde getirmektedir. Ancak, \u00f6l\u00e7e\u011fi, metodolojik titizli\u011fi ve ayr\u0131nt\u0131l\u0131 risk stratifikasyonu ile elde edilen sonu\u00e7lar\u0131n g\u00fcvenilirli\u011fini art\u0131rmaktad\u0131r. Gelecekte molek\u00fcler ve genetik tumor profillemesi ile klinik parametrelerin entegre edilmesi, diferansiye tiroid kanseri y\u00f6netiminde bireyselle\u015ftirilmi\u015f tedavi stratejilerinin daha da iyile\u015ftirilmesini sa\u011flayacakt\u0131r.<\/p>\n
Sonu\u00e7 olarak, bu \u00e7\u0131\u011f\u0131r a\u00e7\u0131c\u0131 \u00e7al\u0131\u015fmada cerrahi sonras\u0131 RAI tedavisinin, diferansiye tiroid kanserinde farkl\u0131 histolojik alt tipler ve risk gruplar\u0131nda uzun vadeli g\u00f6receli sa\u011fkal\u0131m\u0131 belirgin bi\u00e7imde art\u0131rd\u0131\u011f\u0131 ortaya konmu\u015ftur. \u00d6zellikle d\u00fc\u015f\u00fck ve orta riskli hastalarda uygulamaya y\u00f6nelik mevcut paradigmalar\u0131n yeniden de\u011ferlendirilmesi gerekti\u011fi vurgulanmakta; n\u00fckleer t\u0131p ve endokrinoloji alanlar\u0131nda klinik uygulamalar\u0131 y\u00f6nlendirecek \u00f6nemli ve de\u011ferli bir kan\u0131t taban\u0131 olu\u015fturulmaktad\u0131r. Tedavi faydalar\u0131n\u0131n maksimize edilmesi ve a\u015f\u0131r\u0131 tedaviden ka\u00e7\u0131n\u0131lmas\u0131 aras\u0131ndaki denge korunarak precision onkoloji yakla\u015f\u0131m\u0131nda RAI\u2019nin rol\u00fc daha net anla\u015f\u0131lm\u0131\u015ft\u0131r.<\/p>\n
—<\/p>\n
Ara\u015ft\u0131rma Konusu<\/strong>: Makale Ba\u015fl\u0131\u011f\u0131<\/strong>: Haberin Yay\u0131n Tarihi<\/strong>: Resim Credits<\/strong>: Anahtar Kelimeler<\/strong>: Differansiye tiroid kanseri, d\u00fcnya genelinde en s\u0131k te\u015fhis edilen endokrin maligniteler aras\u0131nda yer almaktad\u0131r. Cerrahi rezeksiyonu takiben kullan\u0131lan radyoaktif iyot (RAI) tedavisi, \u00f6zellikle y\u00fcksek riskli hastalarda y\u0131llard\u0131r etkin bir tedavi y\u00f6ntemi olarak uygulanm\u0131\u015ft\u0131r. Ancak, d\u00fc\u015f\u00fck ve orta riskli diferansiye tiroid kanseri hastalar\u0131nda RAI tedavisinin uzun vadeli sa\u011fkal\u0131m \u00fczerine etkisi klinik anlamda tart\u0131\u015fmal\u0131 kalmaya devam etmi\u015ftir….<\/p>\n","protected":false},"author":1,"featured_media":3914,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_yoast_wpseo_title":"","_yoast_wpseo_metadesc":"","_yoast_wpseo_focuskw":"","rank_math_title":"","rank_math_description":"","rank_math_focus_keyword":"","_wpan_schema_json_ld":"","_wpan_ai_seo_metadata":"","_wpan_ai_seo_status":"","_wpan_ai_seo_policy":"","_wpan_ai_seo_faq_block":"","_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[28],"tags":[3313,3315,3311,3314,3312],"tmauthors":[],"class_list":{"0":"post-3913","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-kanser","8":"tag-dusuk-ve-orta-riskli-diferansiye-tiroid-kanseri-tedavi-sonuclari","9":"tag-papiller-ve-folikuler-tiroid-kanseri-rai-tedavisi-avantajlari","10":"tag-radyoaktif-iyot-tedavisi-farklilasmis-tiroid-kanseri-sagkalimi","11":"tag-seer-veritabani-tiroid-kanseri-sagkalim-analizi","12":"tag-yuksek-riskli-tiroid-kanseri-icin-rai-tedavisinin-etkisi"},"jetpack_featured_media_url":"https:\/\/haber360.com\/wp-content\/uploads\/2025\/04\/Radyoiyot-Tedavisi-ile-Farklilasmis-Tiroid-Kanseri-Sagkalimi-1745598578.jpg","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/posts\/3913","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/comments?post=3913"}],"version-history":[{"count":0,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/posts\/3913\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/media\/3914"}],"wp:attachment":[{"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/media?parent=3913"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/categories?post=3913"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/tags?post=3913"},{"taxonomy":"tmauthors","embeddable":true,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/tmauthors?post=3913"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
\nRadyoaktif iyot tedavisinin papiller ve folik\u00fcler tiroid kanserinde histolojik alt tiplere ve n\u00fcks risk kategorilerine g\u00f6re uzun vadeli g\u00f6receli sa\u011fkal\u0131m \u00fczerindeki etkisi.<\/p>\n
\nOpen Access Impact of Radioactive Iodine Treatment on Long-Term Relative Survival in Patients with Papillary and Follicular Thyroid Cancer: A SEER-Based Study Covering Histologic Subtypes and Recurrence Risk Categories<\/p>\n
\n1 Nisan 2025<\/p>\n
\nDr. Henning Weis, PhD, MD ve Prof. Matthias Schmidt, MD, FEBNM, Department of Nuclear Medicine, University Hospital of Cologne<\/p>\n
\nTiroid kanseri, Radyoaktif iyot tedavisi, Diferansiye tiroid kanseri, Papiller tiroid kanseri, Folik\u00fcler tiroid kanseri, G\u00f6receli sa\u011fkal\u0131m, SEER veritaban\u0131, N\u00fckleer t\u0131p, Kanser tedavisi, Precision medicine, Endokrin onkoloji, Uzun vadeli sa\u011fkal\u0131m<\/p>\n","protected":false},"excerpt":{"rendered":"